Nuvation Bio’s recent approval of IBTROZITM for advanced ROS1-positive lung cancer marks a significant milestone in the fight against this challenging cancer subtype. This development not only enhances treatment options for patients in Japan but also underscores the strategic collaboration with Nippon Kayaku to expand access to innovative therapies.
NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC). As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commercial
Source: Original Press Release
